RS60716B1 - Kombinovane terapije koje obuhvataju imidazopirazinone za lečenje psihijatrijskih i/ili kognitivnih poremećaja - Google Patents
Kombinovane terapije koje obuhvataju imidazopirazinone za lečenje psihijatrijskih i/ili kognitivnih poremećajaInfo
- Publication number
- RS60716B1 RS60716B1 RS20200975A RSP20200975A RS60716B1 RS 60716 B1 RS60716 B1 RS 60716B1 RS 20200975 A RS20200975 A RS 20200975A RS P20200975 A RSP20200975 A RS P20200975A RS 60716 B1 RS60716 B1 RS 60716B1
- Authority
- RS
- Serbia
- Prior art keywords
- imidazopyrazinones
- psychiatric
- treatment
- cognitive disorders
- combination treatments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201600659 | 2016-10-28 | ||
EP17791080.9A EP3532064B1 (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
PCT/EP2017/077497 WO2018078038A1 (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
RS60716B1 true RS60716B1 (sr) | 2020-09-30 |
Family
ID=60186299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20200975A RS60716B1 (sr) | 2016-10-28 | 2017-10-26 | Kombinovane terapije koje obuhvataju imidazopirazinone za lečenje psihijatrijskih i/ili kognitivnih poremećaja |
Country Status (29)
Country | Link |
---|---|
US (1) | US10905688B2 (sr) |
EP (1) | EP3532064B1 (sr) |
JP (1) | JP2019536762A (sr) |
KR (1) | KR20190075068A (sr) |
CN (1) | CN109803658A (sr) |
AR (1) | AR109991A1 (sr) |
AU (1) | AU2017350473A1 (sr) |
BR (1) | BR112018013247A2 (sr) |
CA (1) | CA3041607A1 (sr) |
CL (1) | CL2019001091A1 (sr) |
CO (1) | CO2019002909A2 (sr) |
CY (1) | CY1123396T1 (sr) |
DK (1) | DK3532064T3 (sr) |
ES (1) | ES2816005T3 (sr) |
HR (1) | HRP20201326T1 (sr) |
HU (1) | HUE050403T2 (sr) |
IL (1) | IL265635A (sr) |
LT (1) | LT3532064T (sr) |
MA (1) | MA46611B1 (sr) |
ME (1) | ME03821B (sr) |
MX (1) | MX2019004763A (sr) |
PL (1) | PL3532064T3 (sr) |
PT (1) | PT3532064T (sr) |
RS (1) | RS60716B1 (sr) |
RU (1) | RU2019109039A (sr) |
SG (1) | SG11201903770UA (sr) |
SI (1) | SI3532064T1 (sr) |
WO (1) | WO2018078038A1 (sr) |
ZA (1) | ZA201902091B (sr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
RS60716B1 (sr) | 2016-10-28 | 2020-09-30 | H Lundbeck As | Kombinovane terapije koje obuhvataju imidazopirazinone za lečenje psihijatrijskih i/ili kognitivnih poremećaja |
BR112020014177A2 (pt) | 2018-02-01 | 2020-12-08 | Japan Tobacco, Inc. | Composto de amida heterocíclica nitrogenada, e uso do mesmo para finalidades médicas |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
AU2004235915B2 (en) | 2003-05-09 | 2010-08-05 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
KR101222330B1 (ko) | 2007-05-11 | 2013-01-15 | 화이자 인코포레이티드 | 아미노-헤테로시클릭 화합물 |
AU2008329072A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10 |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
PE20110383A1 (es) | 2008-09-08 | 2011-07-15 | Boehringer Ingelheim Int | Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a) |
BRPI0922351A2 (pt) | 2008-12-06 | 2018-06-05 | Intracellular Therapies Inc | compostos orgânicos |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
JP5879336B2 (ja) | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
MX342782B (es) | 2010-08-12 | 2016-10-12 | Eli Lilly And Company * | Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos. |
RU2603140C2 (ru) | 2010-09-20 | 2016-11-20 | Айронвуд Фармасьютикалз, Инк. | Соединения имидазотриазинона |
US20130196986A1 (en) | 2010-09-21 | 2013-08-01 | Marc Labroli | Triazolopyrazinones as p2x7 receptor antagonists |
JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
AR085840A1 (es) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona |
US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
IN2015DN02829A (sr) * | 2011-10-10 | 2015-09-11 | Lundbeck & Co As H | |
WO2013110768A1 (en) | 2012-01-26 | 2013-08-01 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
ES2904267T3 (es) | 2012-06-18 | 2022-04-04 | Dart Neuroscience Llc | Composiciones farmacéuticas de derivados de 6H-pirido[3.2-e][1.2.4]triazolo[1,5-c]pirimidina-5-ona y[1.2.4]triazolo[1,5-c]pteridina-5(6H)-ona como inhibidores de PDE1 para el tratamiento, por ejemplo, de trastornosneurológicos |
KR102240326B1 (ko) | 2013-03-15 | 2021-04-13 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
AU2015220873A1 (en) | 2014-02-19 | 2016-08-11 | H. Lundbeck A/S | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease |
JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
US20170273985A1 (en) | 2014-09-18 | 2017-09-28 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
WO2016147659A1 (en) | 2015-03-16 | 2016-09-22 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
JO3627B1 (ar) * | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
US20180244645A1 (en) | 2015-08-12 | 2018-08-30 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors |
CN105254635A (zh) * | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
JP2018076285A (ja) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体を含む医薬 |
US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
RS60716B1 (sr) | 2016-10-28 | 2020-09-30 | H Lundbeck As | Kombinovane terapije koje obuhvataju imidazopirazinone za lečenje psihijatrijskih i/ili kognitivnih poremećaja |
MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
-
2017
- 2017-10-26 RS RS20200975A patent/RS60716B1/sr unknown
- 2017-10-26 DK DK17791080.9T patent/DK3532064T3/da active
- 2017-10-26 EP EP17791080.9A patent/EP3532064B1/en active Active
- 2017-10-26 CN CN201780063182.9A patent/CN109803658A/zh active Pending
- 2017-10-26 PT PT177910809T patent/PT3532064T/pt unknown
- 2017-10-26 SI SI201730388T patent/SI3532064T1/sl unknown
- 2017-10-26 BR BR112018013247A patent/BR112018013247A2/pt not_active Application Discontinuation
- 2017-10-26 MA MA46611A patent/MA46611B1/fr unknown
- 2017-10-26 WO PCT/EP2017/077497 patent/WO2018078038A1/en unknown
- 2017-10-26 ME MEP-2020-170A patent/ME03821B/me unknown
- 2017-10-26 LT LTEP17791080.9T patent/LT3532064T/lt unknown
- 2017-10-26 AU AU2017350473A patent/AU2017350473A1/en not_active Abandoned
- 2017-10-26 SG SG11201903770UA patent/SG11201903770UA/en unknown
- 2017-10-26 RU RU2019109039A patent/RU2019109039A/ru not_active Application Discontinuation
- 2017-10-26 JP JP2019522523A patent/JP2019536762A/ja active Pending
- 2017-10-26 PL PL17791080T patent/PL3532064T3/pl unknown
- 2017-10-26 CA CA3041607A patent/CA3041607A1/en not_active Abandoned
- 2017-10-26 US US16/345,136 patent/US10905688B2/en active Active
- 2017-10-26 KR KR1020197011509A patent/KR20190075068A/ko not_active Application Discontinuation
- 2017-10-26 HU HUE17791080A patent/HUE050403T2/hu unknown
- 2017-10-26 MX MX2019004763A patent/MX2019004763A/es unknown
- 2017-10-26 ES ES17791080T patent/ES2816005T3/es active Active
- 2017-10-27 AR ARP170102997A patent/AR109991A1/es unknown
-
2019
- 2019-03-26 IL IL265635A patent/IL265635A/en unknown
- 2019-03-27 CO CONC2019/0002909A patent/CO2019002909A2/es unknown
- 2019-04-03 ZA ZA2019/02091A patent/ZA201902091B/en unknown
- 2019-04-22 CL CL2019001091A patent/CL2019001091A1/es unknown
-
2020
- 2020-08-24 CY CY20201100788T patent/CY1123396T1/el unknown
- 2020-08-25 HR HRP20201326TT patent/HRP20201326T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US10905688B2 (en) | 2021-02-02 |
HRP20201326T1 (hr) | 2020-11-27 |
AR109991A1 (es) | 2019-02-13 |
AU2017350473A1 (en) | 2019-04-18 |
SI3532064T1 (sl) | 2020-10-30 |
DK3532064T3 (da) | 2020-08-24 |
LT3532064T (lt) | 2020-09-25 |
RU2019109039A (ru) | 2020-11-30 |
SG11201903770UA (en) | 2019-05-30 |
US20190282571A1 (en) | 2019-09-19 |
ES2816005T3 (es) | 2021-03-31 |
IL265635A (en) | 2019-05-30 |
JP2019536762A (ja) | 2019-12-19 |
CY1123396T1 (el) | 2021-12-31 |
CL2019001091A1 (es) | 2019-07-05 |
EP3532064A1 (en) | 2019-09-04 |
MA46611B1 (fr) | 2020-08-31 |
PT3532064T (pt) | 2020-09-03 |
CO2019002909A2 (es) | 2019-06-19 |
EP3532064B1 (en) | 2020-07-29 |
MA46611A (fr) | 2019-09-04 |
WO2018078038A1 (en) | 2018-05-03 |
HUE050403T2 (hu) | 2020-12-28 |
RU2019109039A3 (sr) | 2021-01-29 |
MX2019004763A (es) | 2019-07-01 |
BR112018013247A2 (pt) | 2018-12-04 |
CN109803658A (zh) | 2019-05-24 |
ZA201902091B (en) | 2020-10-28 |
PL3532064T3 (pl) | 2020-11-16 |
KR20190075068A (ko) | 2019-06-28 |
CA3041607A1 (en) | 2018-05-03 |
ME03821B (me) | 2021-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
IL271085A (en) | Bacteria to treat disorders | |
ZA201902091B (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
SG10202111885PA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
IL271117B (en) | Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders | |
ZA201901055B (en) | Treatment and prevention of sleep disorders | |
IL271072A (en) | Devices and methods for the treatment of body surface disorders | |
ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
IL275654A (en) | Methods of treating CASTOR-related disorders | |
IL272097A (en) | Compounds for the prevention and treatment of medical disorders and their uses | |
RS64074B1 (sr) | Kombinacije imetelstata i venetoklaksa za lečenje akutne mijeloidne leukemije | |
EP3723742C0 (fr) | Utilisation de la fluoroethylnormemantine pour la prevention et le traitement de l'anxiete | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
HK1257911A1 (zh) | 7,8二羥基黃酮在治療或預防老齡化相關的認知能力下降中的用途 | |
IL274132A (en) | Treatment of skin problems | |
IL268844A (en) | Peptides and methods of treating dystrophy-related diseases by them | |
SG11202007642RA (en) | Treatment of disorders with tasimelteon | |
GB201612030D0 (en) | Combination therapy for the treatment of head and neck cancers | |
GB201700502D0 (en) | Treatment of tumours of the central nervous system | |
GB201602011D0 (en) | Treating skin disorders |